Serum YKL-40 Predicts Adverse Clinical Outcomes in Patients With Chronic Heart Failure
Authors:
- Yasuchika TakeishiYTYasuchika Takeishi
- Tatsuro KitaharaTKTatsuro Kitahara
- Mitsunori IshinoMIMitsunori Ishino
- Toshiki SasakiTSToshiki Sasaki
- Satoshi SuzukiSSSatoshi Suzuki
- Tetsuro ShishidoTSTetsuro Shishido
- Isao KubotaIKIsao Kubota
- 1 November 2010
- journal article
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 16 (11) , 873-879
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
- Fukuda Foundation for Medical Technology
- Takeda Science Foundation
- Uehara Memorial Foundation
This publication has 34 references indexed in Scilit:
- Serum levels of YKL-40 increases in patients with acute myocardial infarctionCoronary Artery Disease, 2008
- High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortalityClinical and Experimental Immunology, 2007
- Serum YKL-40 levels in patients with coronary artery diseaseCoronary Artery Disease, 2007
- High Serum Concentration of YKL-40 Is Associated with Short Survival in Patients with Acute Myeloid LeukemiaClinical Cancer Research, 2005
- Immune Activation in Chronic Heart FailureThe American Journal of Cardiology, 2005
- Modulation of Doxorubicin-Induced Cardiac Dysfunction in Toll-Like Receptor-2–Knockout MiceCirculation, 2004
- Toll-Like Receptor-2 Modulates Ventricular Remodeling After Myocardial InfarctionCirculation, 2003
- Serum Level of YKL-40 is Elevated in Patients with Streptococcus pneumoniae Bacteremia and is Associated with the Outcome of the DiseaseScandinavian Journal of Infectious Diseases, 2002
- Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD)JACC, 1996
- Changing epidemiological features of cardiac failureHeart, 1994